Early Minimal Residual Disease (MRD) Analysis During Treatment of Philadelphia Chromosome / Bcr-Abl Positive Acute Lymphoblastic Leukemia (Ph + ALL) with the Abl-Tyrosine Kinase Inhibitor STI571 (Glivec) Analysis in Ph + ALL During STI571 Treatment
暂无分享,去创建一个
Harald | O. Ottmann | B. Wassmann | D. Hoelzer | H. Pfeifer | U. Scheuring | E. Petershofen | J. Atta | P. Brück | B. Gehrke | Gschaidmeier